KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Regeneron Pharmaceuticals (REGN) Leases (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has disclosed Leases for 12 consecutive years, with $576.7 million as the latest value for Q4 2025.

  • For Q4 2025, Leases fell 2.45% year-over-year to $576.7 million; the TTM value through Dec 2025 reached $576.7 million, down 2.45%, while the annual FY2025 figure was $576.7 million, 2.45% down from the prior year.
  • Leases hit $576.7 million in Q4 2025 for Regeneron Pharmaceuticals, down from $591.2 million in the prior quarter.
  • Across five years, Leases topped out at $631.3 million in Q4 2021 and bottomed at $576.7 million in Q4 2025.
  • Average Leases over 5 years is $605.0 million, with a median of $605.7 million recorded in 2023.
  • Year-over-year, Leases decreased 1.74% in 2022 and then dropped 2.45% in 2025.
  • Regeneron Pharmaceuticals' Leases stood at $631.3 million in 2021, then dropped by 1.74% to $620.3 million in 2022, then dropped by 2.35% to $605.7 million in 2023, then decreased by 2.39% to $591.2 million in 2024, then decreased by 2.45% to $576.7 million in 2025.
  • According to Business Quant data, Leases over the past three periods came in at $576.7 million, $591.2 million, and $605.7 million for Q4 2025, Q4 2024, and Q4 2023 respectively.